Key Advantages


Our pipeline include antibodies addressing two receptors, progressing into pre clinical stage:

Immune Oncology

Clinical Indications:
Metastatic melanoma

Immune Oncology

  • Higher certainty for generating the targeted-specific antibodies
  • Selective blocking of a single target among closely related ensemble of targets, which allows:
    1. Specific and exclusive blocking of ligand/receptor binding domain, aiming to increase response rate among patients.
    2. Eliminating binding of conflicting ligands/receptors such as inhibitory versus activatory modulators typical to immune checkpoint functions.







© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet